A detailed history of Rhumbline Advisers transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 98,097 shares of RCKT stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
98,097
Previous 101,134 3.0%
Holding current value
$1.15 Million
Previous $2.18 Million 16.81%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$17.6 - $25.88 $53,451 - $78,597
-3,037 Reduced 3.0%
98,097 $1.81 Million
Q2 2024

Aug 01, 2024

BUY
$20.66 - $26.72 $102,432 - $132,477
4,958 Added 5.16%
101,134 $2.18 Million
Q1 2024

May 09, 2024

BUY
$26.16 - $30.74 $108,904 - $127,970
4,163 Added 4.52%
96,176 $2.59 Million
Q4 2023

Feb 08, 2024

BUY
$16.78 - $31.94 $75,275 - $143,282
4,486 Added 5.13%
92,013 $2.76 Million
Q3 2023

Nov 09, 2023

BUY
$15.07 - $24.05 $59,767 - $95,382
3,966 Added 4.75%
87,527 $1.79 Million
Q2 2023

Aug 08, 2023

SELL
$16.59 - $23.6 $143,685 - $204,399
-8,661 Reduced 9.39%
83,561 $1.66 Million
Q1 2023

May 11, 2023

BUY
$15.79 - $22.6 $111,003 - $158,878
7,030 Added 8.25%
92,222 $1.58 Million
Q4 2022

Feb 14, 2023

BUY
$15.5 - $22.76 $231,508 - $339,943
14,936 Added 21.26%
85,192 $1.67 Million
Q3 2022

Nov 10, 2022

BUY
$12.37 - $18.41 $48,997 - $72,922
3,961 Added 5.97%
70,256 $1.12 Million
Q2 2022

Aug 11, 2022

BUY
$7.96 - $16.64 $172,278 - $360,139
21,643 Added 48.47%
66,295 $912,000
Q1 2022

May 12, 2022

BUY
$13.16 - $23.68 $20,727 - $37,296
1,575 Added 3.66%
44,652 $708,000
Q4 2021

Feb 10, 2022

SELL
$21.52 - $36.02 $28,384 - $47,510
-1,319 Reduced 2.97%
43,077 $940,000
Q3 2021

Nov 12, 2021

BUY
$27.42 - $48.97 $46,943 - $83,836
1,712 Added 4.01%
44,396 $1.33 Million
Q2 2021

Aug 05, 2021

SELL
$39.41 - $47.25 $10,049 - $12,048
-255 Reduced 0.59%
42,684 $1.89 Million
Q1 2021

May 06, 2021

SELL
$43.34 - $65.91 $130,063 - $197,795
-3,001 Reduced 6.53%
42,939 $1.91 Million
Q4 2020

Feb 10, 2021

BUY
$23.3 - $59.57 $9,483 - $24,244
407 Added 0.89%
45,940 $2.52 Million
Q3 2020

Nov 12, 2020

SELL
$20.5 - $28.59 $121,975 - $170,110
-5,950 Reduced 11.56%
45,533 $1.04 Million
Q2 2020

Aug 13, 2020

BUY
$13.32 - $22.61 $160,386 - $272,247
12,041 Added 30.53%
51,483 $1.08 Million
Q1 2020

May 06, 2020

BUY
$9.71 - $25.11 $18,924 - $48,939
1,949 Added 5.2%
39,442 $550,000
Q4 2019

Feb 05, 2020

BUY
$11.07 - $24.23 $7,416 - $16,234
670 Added 1.82%
37,493 $853,000
Q3 2019

Oct 23, 2019

SELL
$10.85 - $14.78 $1,519 - $2,069
-140 Reduced 0.38%
36,823 $429,000
Q2 2019

Aug 14, 2019

BUY
$15.0 - $19.81 $94,020 - $124,169
6,268 Added 20.42%
36,963 $554,000
Q1 2019

May 01, 2019

BUY
$13.45 - $19.01 $34,606 - $48,912
2,573 Added 9.15%
30,695 $538,000
Q4 2018

Jan 31, 2019

BUY
$11.21 - $23.53 $101,293 - $212,617
9,036 Added 47.34%
28,122 $417,000
Q3 2018

Nov 07, 2018

SELL
$18.5 - $25.49 $22,218 - $30,613
-1,201 Reduced 5.92%
19,086 $470,000
Q2 2018

Aug 06, 2018

BUY
$14.58 - $23.0 $295,784 - $466,601
20,287 New
20,287 $398,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $884M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.